Navigation Links
U.S. Department of Energy Hails Dilon Diagnostics as a Medical Technology Pioneer and Top National Innovator
Date:3/31/2011

NEWPORT NEWS, Va., March 31, 2011 /PRNewswire/ -- The U.S. Department of Energy has acclaimed Dilon Diagnostics as a success story in the field of medical technology and innovation for commercializing the technologies of the national laboratories. According to the government agency, Dilon and similar entrepreneurs, "build the new industries of the 21st century, and help solve some of our toughest global challenges."

The Dilon 6800® digital gamma camera is based on gamma-imaging technology developed at the U.S. Department of Energy's Thomas Jefferson National Accelerator Facility in Newport News, Va. The medical procedure that this advanced imaging technology enables is known as Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI), and reveals cancerous lesions even at very early stages. BSGI/MBI is a proven technology that can find cancers missed by mammography and ultrasound.

"We are honored to be acknowledged by the Department of Energy as one the country's successful innovators in the medical technology field," said Bob Moussa, President and CEO of Dilon. "We have been able to make a significant impact by utilizing our licensing agreement with Jefferson Lab to help save lives."

Dilon sells its products across Europe, Asia, and the U.S., and recently signed on distributors in Mexico, Australia and Russia Many leading medical centers around the country are now offering BSGI/MBI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. More than 250,000 patients have been screened with BSGI/MBI on a worldwide basis.

About BSGI/MBI

As a follow-up to mammography, BSGI/MBI utilizes the Dilon 6800® Gamma Camera to help physicians see the breast more clearly and differentiate benign from malignant tissue. To perform BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the
'/>"/>

SOURCE Dilon Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
2. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Chester County Dairy
3. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
4. DuPont Provides Technology for Washington Hospital Centers Emergency Department
5. NYC Department of Healths Get Some NYC Condoms Sends Wrong Message and Misuses Tax Dollars, says MIM President Bob Peters
6. PA Department of Health Reports Rise in Flu Activity; Reminds Public of Need for Flu Shot
7. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
8. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Lebanon County Dairy
9. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
10. Justice Department Will Not Oppose CEO Roundtable on Cancers Proposal
11. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... 27, 2011 As a result of the flagging ... dangerous to their health, according to Consumer Reports, annual ... take a prescription medicine told pollsters they,d cut health-care ... or medical procedure, declining tests, or ordering cheaper drugs ...
... ( http://www.myprgenie.com ) --  Texans for Stem Cell Research ... panel of stem cell experts from Texas and around ... TSCR Second Annual Educational Symposium with a welcome address ... Health Affairs for The University of Texas System. The ...
Cached Medicine Technology:Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 2Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 3Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 4Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 5World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 2World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 3World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 4World-Class Stem Cell Pioneers Collaborate & Educate at Texans for Stem Cell Research 2nd Annual Symposium In Austin 5
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is ... repair a damaged mitral valve as the heart continues ... by Abbott Vascular , is designed to treat ... in which the heart’s mitral valve leaflets fail to ... heart’s left ventricle into the left atrium. The heart ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... 21 Patient Safety Week was March 8-14. ... (1979), the pulse oximeter (1983) and the brain activity ... of these technological devices clearly improved patient safety. This ... a forward thinking, caring physician."Until now, I,ve never publicly ...
... MI based company, is researching and developing decontamination testing equipment ... use their extensive knowledge of cleaning and decontamination to develop repeatable ... ... (Vocus) April 21, 2009 -- Midbrook, Inc ., a Jackson, ...
... medical billing company, announces services that help medical professionals go paperless, ... the healthcare industry. , ... (PRWEB) April 21, 2009 ... upon the nation,s healthcare system to step up efforts to convert ...
... worldwide for self-directed home treatment of the most common cause of ... ... Edmonton, Canada (PRWEB) April 14, 2009 -- A new ... treatment of BPPV (Benign Paroxysmal Positional Vertigo), the most common ...
... 21 The University HealthSystem Consortium (UHC) today ... for employee satisfaction surveys and consulting services to ... agreement, which has 2 optional 1-year renewal periods, ... an extensive array of customized surveys and analyses ...
... the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory ... of supplemental new drug applications (sNDA) for SEROQUEL XR (quetiapine ... disorder (MDD) and generalized anxiety disorder (GAD).The Advisory Committee concluded: ... SEROQUEL XR was shown to be ...
Cached Medicine News:Health News:American Society of Anesthesiologists Recent Public Debate Comes to Dead End 2Health News:American Society of Anesthesiologists Recent Public Debate Comes to Dead End 3Health News:Midbrook Tackles Medical Decontamination 2Health News:Midbrook Tackles Medical Decontamination 3Health News:Dr. America Comes to Obama's Aid, Helps Doctors Digitize 2Health News:Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo 2Health News:Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo 3Health News:University HealthSystem Consortium Selects Morehead to Provide Employee Satisfaction and Consulting Services 2Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 2Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 3Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 4Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 5Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 6Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 7
Malaria device / strip (3 line, P.f/P.v Ag Test-pLDH)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
BioSign® Malaria - Rapid Malaria Antigen Test...
Medicine Products: